Janus Henderson Group Q1 2026 13F Holdings and Activity Report

I. Institutional Overview

A defining characteristic of Janus Henderson’s current investment posture is its extreme diversification. With a total of 2,354 individual stock holdings , the institution operates with a breadth that few other active managers can match. This high number of holdings suggests a multi-strategy approach where various fund managers within the group exercise autonomy over different sectors and geographies. However, despite this vast number of positions, the institution maintains a clear "heavyweight" focus on core conviction names, particularly within the technology and healthcare sectors. This duality—vast diversification across thousands of stocks paired with concentrated bets in the top 1% of the portfolio—reveals a psychological portrait of an institution that seeks to capture broad market "beta" while aggressively pursuing "alpha" through its largest allocations.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

II. Sector Allocation Analysis

Healthcare stands as the second-largest pillar at 19.05%. This is a significant allocation that serves as a "growth-defensive" hybrid. While biotechnology and pharmaceutical companies offer high growth potential through drug pipelines and innovation, the sector also provides a buffer against economic downturns due to the inelastic demand for medical services. The institution’s move to maintain nearly a fifth of its assets in healthcare signals a cautious stance toward the broader economic cycle, ensuring that the portfolio has "ballast" if growth in other sectors slows.

From this allocation, we can infer that Janus Henderson’s macro outlook is one of "selective growth." They are avoiding the most cyclical and commodity-dependent areas of the market, instead focusing on sectors with high intellectual property value and structural tailwinds. The high weight in Healthcare and Industrials alongside Tech suggests they are preparing for a "higher-for-longer" interest rate environment where only companies with strong balance sheets and essential products can thrive. They are not betting on a massive economic boom that would lift all boats (which would require more Energy and Materials), but rather a bifurcated market where innovation-led sectors continue to lead.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

III. Top 10 Holdings Deep Dive

NVIDIA remains the crown jewel of the Janus Henderson portfolio, occupying a massive 7.15% weight. This is a "conviction holding" in the truest sense. Despite the stock's meteoric rise and the potential for volatility in the semiconductor sector, the institution added a marginal 0.23% to its position this quarter. This small addition, while seemingly minor, is significant because it shows that even at record valuations, Janus Henderson is not yet ready to take major profits. The increase in portfolio weight from 6.89% to 7.15% was largely driven by the stock's price appreciation, but the fact that they didn't trim the position suggests they believe the AI infrastructure cycle has further to run. NVIDIA represents the institution’s primary bet on the "computational gold rush," serving as the foundational asset for their entire technology strategy.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

IV. Major Buys/Additions

The most significant operation this quarter was the massive accumulation of AstraZeneca. With an estimated addition of $2.20 billion , this was not a mere tactical adjustment but a profound strategic shift. AstraZeneca has transformed from a minor holding into a top 10 cornerstone. This move can be qualified as a " growth acceleration bet ." The institution likely sees AstraZeneca as the premier play in the global oncology market, with its "blockbuster" drugs and robust R&D pipeline providing a high degree of earnings certainty. In a market where tech valuations are stretched, moving over $2 billion into a high-quality pharmaceutical giant represents a move toward "defensive growth"—seeking capital appreciation while insulating the portfolio from tech-specific volatility.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

V. Major Sells and Exits

The most impactful selling operations were the massive reductions in Microsoft and Amazon, totaling over $2.1 billion in realized capital. These should be qualified as " Major Strategic Contractions ." For an institution like Janus Henderson, these stocks are the ultimate "safe havens." Reducing them by 11% and 15% respectively is a loud signal that the institution believes the "easy gains" are over. This is not a lack of faith in the companies' fundamentals, but rather a disciplined response to high valuations. By retrieving over $2 billion from just two names, the institution created the "dry powder" necessary to fund the massive $2.2 billion entry into AstraZeneca. This is a textbook example of "Sell A to Buy B" sector rotation—moving from high-multiple software/cloud to more reasonably valued healthcare.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

VI. Investment Insights and Risk Warnings

The logic chain is clear: 1. Sold what: Trillion-dollar tech leaders and mature SaaS platforms. 2. Why sell: To lock in historic profits and reduce concentration risk at the top of the portfolio. 3. Bought what: Global pharmaceutical leaders (AstraZeneca), energy transition industrials (GE Vernova), and specialized biotech (Madrigal). 4. Why buy: To capture the next wave of structural growth in oncology, grid modernization, and breakthrough medicine, which offer better risk-adjusted returns than overextended tech. 5. Result: A more resilient, diversified portfolio that is less dependent on the "AI hype cycle" and more aligned with long-term global demographic and infrastructure trends.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

Sources and limitations

This report uses public U.S. Securities and Exchange Commission Form 13F disclosures and structured data maintained by 13F Hub. A 13F filing is a quarter-end snapshot of reportable long positions, is normally published with a delay, and does not disclose every short position, cash balance, bond, derivative, or non-U.S. asset.

Narrative content is prepared from the same-period SEC disclosure and 13F Hub structured data, then checked before publication. This material is for research and education, not personalized investment advice.